Risk factors for recurrent clostridium difficile infections and strategies to decrease readmissions in a community hospital

Hospital Pharmacy

Volumn 50, Issue 11, 2015, Pages 1003-1010

  Majors, Darrin ^a   Ellis, Patrick ^a  

^a Memorial Health System/CHI   (United States)

Author keywords

Hospital readmissions; Recurrent clostridium difficile; Risk factors; Vancomycin taper

Indexed keywords

METRONIDAZOLE; VANCOMYCIN;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY HOSPITAL; DRUG COST; DRUG EFFICACY; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PATIENT COUNSELING; PRESCRIPTION; PROSPECTIVE STUDY; RECURRENT INFECTION; RISK FACTOR; TREATMENT DURATION;

EID: 84975698837     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj5011-1003     Document Type: Article

References (13)

1. Hu, M, Katchar, K, Kyne, L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009;136:1206-1214.
2. Cohen, SH, Gerding, DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-455.
3. Surawicz, CM, Brandt, LJ, Binion, DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478-498.
4. Marsh, J, Arora, R, Schlackman, J, et al. Recurrent Clostridium difficile disease: Association of relapse with BI/NAP1/027. J Clin Microbiol. 2012;50(12):4078-4082.
5. Eyre W, Walker SA, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: Implications for initial management. Clin Infect Dis. 2012;55(S2):S77-S87.
6. Johnson S. Recurrent Clostridium difficile infection: Causality and therapeutic approaches. Int J Antimicrob Agents. 2009;33(suppl 1):S33-S36.
7. The Centers for Disease Control and Prevention and National Healthcare Safety Network. Multidrug-resistant organism and Clostridium difficile infection (MDRO/CDI) module. http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO-CDADcurrent.pdf. April 2015. Accessed October 7, 2015. July 2013 CDC/NHSN Protocol Clarifications.
8. Drekonja DM, Amundson WH, DeCarolis DD, et al. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med. 2011;124:1081.e1-1081.e7.
9. Garey KW, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect. 2008;70:298-304.
10. Louie, TJ, Miller, MA, Mullane, KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infections. N Engl J Med. 2004;364:422-431.
11. Cornely, OA, Crook, DW, Esposito, R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised trial. Lancet Infect Dis. 2012;12:281-289.
12. See, I, Mu, Y, Cohen, J, et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infect Dis. 2014;58(10):1394-1400.
13. Youngster I, Sauk J, Pindar C, et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: A randomized, open-label, controlled pilot study. Clin Infect Dis. 2014;58(11):1515-1522.